Eloxx To Present CF Data in Early Q4 2021
Insights - Yesterday, Eloxx (ELOX) was down 17% to $1.60 after the company provided an enrolment update for ELX-02 Phase 2 in cystic fibrosis. The company expects to present … Continue Reading
PremiumSearch Results for gene therapy
Eloxx Risk-Reward Compelling Ahead of Cystic Fibrosis Data
Research - Eloxx (ELOX) is developing a cystic fibrosis treatment for the 12% of patients that Vertex’s therapies cannot treat. The mechanism of action in the ribosome … Continue Reading
Premium
Magenta’s MGTA-145 Mobilizes Multiple Myeloma Patients
Insights - Magenta reported preliminary data from their Phase 2 in mobilizing Multiple Myeloma patients and it was phenomenal. Concurrently, with the data announcement, Magenta also closed a $86M financing with … Continue Reading
Premium
What to Expect for ASCO21
Research - The ASCO 2021 meeting is going to be June 4-8. This morning, ASCO 2021 abstract titles were released. May 19th is when selected abstracts (details other than just … Continue Reading
Premium
Notes from Affimed’s KOL Call Discussing AACR NK+AFM13
Insights - Affimed(AFMD) hosted a call after market today to discuss cbNK+AFM13 data presented at AACR. KOL from MD Anderson Dr. Katy Rezvani was also on the call. Below … Continue Reading
Premium
9Meters Has a Novel MoA for SBS That Could Be Worth Billions
Research - 9 Meters (NMTR) is developing a novel treatment for short bowel syndrome (“SBS”) by focusing on slowing food transit time through the gastrointestinal (“GI”) tract. … Continue Reading
Premium
Bio Downturn Presents Buying Opportunity in These Names
Research - Nine Meters Biopharma (NMTR) NMTR has reported top-line Phase 1b/2a data for Short Bowel Syndrome (“SBS”). The gastrointestinal (“GI”) tract is the tract from the mouth to the … Continue Reading
Premium